Wraparound support in weight loss Experts have stressed the multi-factorial causes of obesity and therefore the need for a multi-faceted approach, considering other factors like lifestyle, trauma and psychological support 46
The United States Food and Drug Administration (US FDA) granted traditional approval for Leqembi (lecanemab-irmb) on July 6, 2023, for the treatment of AD [17]
What the clinical research actually says about GLP-1 receptor agonists and alcohol cravings
Clinical data asks a harder question: what happens after months of treatment, structured follow-up, adverse-event tracking, and statistical comparison with placebo
This variety prevents nutrient gaps and keeps meals enjoyable during your treatment journey
Sourcing quality considerations The unregulated nature of the peptide market creates quality concerns